CompletedNot Applicable

Peri-operative Oral Triiodothyronine Replacement Therapy to Decrease the Risk of Transient Atrial Fibrillation After Off-pump Coronary Artery Bypass Surgery

South Korea100 participantsStarted 2010-06

Plain-language summary

This study is planned to medicate oral T3(Liothyronine)to the patients who are planned to have OPCAB(off- pump coronary bypass graft surgery. The aim of this study was to assess the effects of oral triiodothyronine (T3) therapy on postoperative thyroid hormone concentrations, hemodynamic variables and outcomes in patients undergoing OPCAB in a randomized, controlled trial.

Who can participate

Age range20 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients who are undergoing Off-pump coronary artery bypass graft Exclusion Criteria: * No normal sinus rhythm, * History of thyroid disease * Abnormal thyroid hormone * Renal dysfunction * Hepatic dysfunction * LVEF \<30% * Recent MI * Active infection 1\~15

What they're measuring

compare the serum T3 concentrations and the number of patients with serum T3 concentrations below the normal range between the groups

Timeframe: until 36 hours after surgery

Trial details

NCT IDNCT01153360

SponsorYonsei University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2011-08

View on ClinicalTrials.gov More Non-thyroidal Illness Syndrome trials